Stock INT INTELLEGO TECHNOLOGIES AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Intellego Technologies AB

Equities

INT

SE0016075063

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 16:29:37 31/05/2024 BST 		5-day change 1st Jan Change
29 SEK -.--% Intraday chart for Intellego Technologies AB -5.84% +71.60%
04-30 Sweden's Intellego Technologies Names CFO MT
04-30 Intellego Technologies AB Appoints Petra Olofsson as Chief Financial Officer CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 341.2 239.2 445.4
Enterprise Value (EV) 1 333 214.9 467.9
P/E ratio -86.1 x -22.8 x 7.32 x
Yield - - -
Capitalization / Revenue 35.9 x 4.04 x 2.36 x
EV / Revenue 35 x 3.63 x 2.47 x
EV / EBITDA -67.2 x -110 x 5.48 x
EV / FCF -47,268,254 x 3,521,117 x -4,087,421 x
FCF Yield -0% 0% -0%
Price to Book 20.1 x 12.2 x 2.95 x
Nbr of stocks (in thousands) 19,611 20,724 26,353
Reference price 2 17.40 11.54 16.90
Announcement Date 24/05/22 27/04/23 25/04/24
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 0.758 7.694 9.505 59.22 189.1
EBITDA 1 -2.598 1.125 -4.956 -1.958 85.34
EBIT 1 -2.822 0.9017 -4.96 -8.702 83.12
Operating Margin -372.32% 11.72% -52.18% -14.69% 43.96%
Earnings before Tax (EBT) 1 -2.84 0.8907 -5.031 -11.53 68.83
Net income 1 -2.84 3.278 -3.962 -9.962 59.6
Net margin -374.64% 42.6% -41.68% -16.82% 31.52%
EPS - 0.2096 -0.2020 -0.5056 2.310
Free Cash Flow - 0.2882 -7.045 61.04 -114.5
FCF margin - 3.75% -74.11% 103.07% -60.55%
FCF Conversion (EBITDA) - 25.62% - - -
FCF Conversion (Net income) - 8.79% - - -
Dividend per Share - - - - -
Announcement Date 18/05/21 18/05/21 24/05/22 27/04/23 25/04/24
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 - - - - 22.6
Net Cash position 1 0.67 1.34 8.24 24.2 -
Leverage (Debt/EBITDA) - - - - 0.2643 x
Free Cash Flow - 0.29 -7.04 61 -114
ROE (net income / shareholders' equity) - 123% -37.2% -54.5% 72.5%
ROA (Net income/ Total Assets) - 14.1% -24.7% -5.37% 24.6%
Assets 1 - 23.22 16.06 185.6 242
Book Value Per Share - 0.2800 0.8600 0.9500 5.740
Cash Flow per Share - 0.1300 0.4500 2.160 0.3100
Capex - 0.01 0.11 0.14 26.2
Capex / Sales - 0.19% 1.17% 0.24% 13.85%
Announcement Date 18/05/21 18/05/21 24/05/22 27/04/23 25/04/24
1SEK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
INTELLEGO TECHNOLOGIES AB Stock Intellego Technologies AB
+71.60% 72.55M
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.64B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. INT Stock
  4. Financials Intellego Technologies AB